Vir Biotechnology, Inc. (VIR) Insider Trading
Over the last 3 months, VIR insiders made 0 open-market buys and 6 sales, a net sale of -$1.2M (SEC Form 4). Over the last 6 months, 193 institutions increased and 124 reduced their position (13F).
Insider Activity
Sentiment
0/100
Buys (3m)
0
Sells (3m)
6
Net (3m)
-$1.2M
Insider trades by month Buys Sells
Jan
Feb
Mar
Apr
May
Jun
Context3-month price -8.3%Institutions accumulating (13F)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Jun 2, 2026 | Napolitano Janetdirector | Sell | 3,200 | $9.45 |
| Jun 2, 2026 | Sabatini Brentofficer: SVP, Chief Accounting Officer | Sell | 379 | $9.45 |
| May 28, 2026 | Napolitano Janetdirector | Grant | 8,000 | — |
| May 28, 2026 | MORE ROBERT Jdirector | Grant | 8,000 | — |
| May 28, 2026 | BISCHOFBERGER NORBERT Wdirector | Grant | 16,000 | $9.10 |
| May 28, 2026 | Hatfield Jeffrey S.director | Grant | 8,000 | — |
| May 28, 2026 | MORE ROBERT Jdirector | Grant | 16,000 | $9.10 |
| May 28, 2026 | BISCHOFBERGER NORBERT Wdirector | Grant | 8,000 | — |
| May 28, 2026 | Sigal Charles Elliottdirector | Grant | 16,000 | $9.10 |
| May 28, 2026 | Farid Ramydirector | Grant | 8,000 | — |
| May 28, 2026 | Napolitano Janetdirector | Grant | 16,000 | $9.10 |
| May 28, 2026 | Farid Ramydirector | Grant | 16,000 | $9.10 |
| May 28, 2026 | Sigal Charles Elliottdirector | Grant | 8,000 | — |
| May 28, 2026 | Hatfield Jeffrey S.director | Grant | 16,000 | $9.10 |
| May 4, 2026 | SATO VICKI Ldirector | Sell | 22,000 | $10.05 |
| Apr 7, 2026 | De Backer Mariannedirector, officer: President and CEO | Sell | 72,559 | $9.16 |
| Apr 2, 2026 | SATO VICKI Ldirector | Sell | 22,000 | $9.07 |
| Mar 24, 2026 | Sabatini Brentofficer: SVP, Chief Accounting Officer | Sell | 7,711 | $9.12 |
| Feb 26, 2026 | Eisner Markofficer: EVP and Chief Medical Officer | Sell | 1,889 | $9.82 |
| Feb 26, 2026 | De Backer Mariannedirector, officer: Chief Executive Officer | Sell | 14,762 | $9.53 |
| Feb 26, 2026 | O'Byrne Jasonofficer: EVP & Chief Financial Officer | Sell | 1,634 | $9.53 |
| Feb 26, 2026 | de Verneuil Vaninaofficer: EVP, General Counsel, Corp Sec | Sell | 13,700 | $9.82 |
| Feb 26, 2026 | Eisner Markofficer: EVP and Chief Medical Officer | Sell | 1,616 | $9.53 |
| Feb 26, 2026 | SATO VICKI Ldirector | Sell | 42,177 | $9.75 |
| Feb 26, 2026 | SATO VICKI Ldirector | Option | 42,377 | $1.49 |
| Feb 26, 2026 | de Verneuil Vaninaofficer: EVP, General Counsel, Corp Sec | Sell | 3,117 | $9.53 |
| Feb 26, 2026 | SATO VICKI Ldirector | Sell | 200 | $10.26 |
| Feb 26, 2026 | Sabatini Brentofficer: SVP, Chief Accounting Officer | Sell | 1,430 | $9.53 |
| Feb 24, 2026 | Eisner Markofficer: EVP and Chief Medical Officer | Sell | 2,089 | $7.45 |
| Feb 24, 2026 | O'Byrne Jasonofficer: EVP & Chief Financial Officer | Sell | 2,089 | $7.45 |
Source: VIR SEC Form 4 filings, latest Jun 2, 2026. For informational purposes only — not investment advice.
Institutional activity (13F)
How institutions changed their VIR positions over the last 6 months (SEC Form 13F).
Increased
193
New positions
96
Reduced
124
Sold out
55
Largest moves
| Institution | Action | Shares | Filed |
|---|---|---|---|
| BLACKROCK, INC. | Increased | 18.0M | May 13, 2026 |
| BLACKROCK, INC. | Increased | 16.3M | Feb 12, 2026 |
| SB INVESTMENT ADVISERS (UK) LTD | Reduced | 13.1M | Feb 18, 2026 |
| ARCH VENTURE MANAGEMENT, LLC | Unchanged | 12.9M | May 15, 2026 |
| ARCH VENTURE MANAGEMENT, LLC | Unchanged | 12.9M | Feb 17, 2026 |
| VANGUARD GROUP INC | Reduced | 12.5M | Jan 29, 2026 |
| SB INVESTMENT ADVISERS (UK) LTD | Reduced | 10.9M | May 18, 2026 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | New Position | 9.2M | May 8, 2026 |
| GSK PLC | Unchanged | 8.6M | May 14, 2026 |
| GSK PLC | New Position | 8.6M | Feb 12, 2026 |
| STATE STREET CORP | Increased | 7.1M | May 15, 2026 |
| STATE STREET CORP | Increased | 6.2M | Feb 13, 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC | New Position | 5.4M | May 15, 2026 |
| GOLDMAN SACHS GROUP INC | Increased | 3.3M | May 15, 2026 |
| FMR LLC | Reduced | 3.2M | Feb 17, 2026 |
Source: SEC Form 13F filings. For informational purposes only — not investment advice.